nasdaqxers
Jefferies Thinks The Stock Will Be Cash Flow Positive In 2024 Shares of small-cap biotech firm Xeris Biopharma Holdings Inc (NASDAQ:XERS) slipped -1% in trading on Thursday, hitting fresh new lows even with a positive outlook update from management. Ahead of planned meetings with investors next week, management updated its guidance for the full year 2022 results. Q4 2022 hedge fund letters, conferences and more Find A Qualified Financial AdvisorEach advisor has been vetted by SmartAsset and is held to a fiduciary standard to act in your best interests. If you're ready to be matched with local ...
ValueWalk
Discusses the partnership and the potential income it might generate with some highlights from the recent Q3 result Technology-based biopharma company Xeris (NASDAQ:XERS) is set to boost its revenue with an upfront cash payment from a research collaboration and option agreement that was secured with mid-cap pharma Horizon Therapeutics (NASDAQ:HZNP). Xeris opened 12.6% higher at $1.43 on the news before traders banked profits, with the stock drifting lower and closing with a 3.9% gain at $1.32 on Wednesday afternoon. Q3 2022 hedge fund letters, conferences and more Find A Qualified Financial Ad...
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら